Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler
Ox40介导的共刺激克服肿瘤诱导的CD8 T细胞外周耐受
基本信息
- 批准号:7894245
- 负责人:
- 金额:$ 15.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AgonistAntibodiesAntibody TherapyCD4 Positive T LymphocytesCD8B1 geneCancer PatientCellsClinical TrialsDataDevelopmentFamilyFamily memberFutureGenerationsImmune responseInterleukin 2 Receptor GammaInterleukin-2Interleukin-4LaboratoriesLeadLigationMalignant NeoplasmsMalignant neoplasm of prostateMediatingMolecularMolecular ProfilingMusPeptidesPeripheralPhase I Clinical TrialsProstatic NeoplasmsRegulationSignal PathwaySignal TransductionT cell anergyT cell responseT-LymphocyteTestingTumor ImmunityTumor Necrosis Factor Receptoranergybasecytokinecytokine therapyfunctional restorationin vivoinsightlymph nodesmembernovel therapeuticsperipheral tolerancepre-clinical researchpromoterpublic health relevancereceptor expressionresearch studytumortumor necrosis factor receptor superfamily member 4
项目摘要
DESCRIPTION (provided by applicant): Tumor-specific CD8 T cell peripheral tolerance can be a major barrier to the generation of potent anti- tumor immunity. Recent studies have begun to examine whether signaling through co-stimulatory molecules can sufficiently boost the immune response to reverse tumor-specific tolerance and promote anti-tumor immunity. To this end, our laboratory and others have focused on the mechanisms through which ligation of the OX40 (CD134) co-stimulatory molecule, a member of tumor necrosis factor receptor (TNFR) super-family, augments CD4 and CD8 T cell expansion, differentiation, and survival. Importantly, several studies have also shown that OX40 is expressed on T cells isolated from the tumor-draining lymph nodes of tumor-bearing hosts and that OX40 engagement can boost anti-tumor immunity in vivo. OX40-mediated signaling has also been shown to overcome peptide-induced CD4 T cell anergy. Recently, we demonstrated that OX40 ligation could restore the function of anergic tumor-reactive CD8 T cells in vivo. Although anti-OX40 therapy led to partial tumor regression, the tumors ultimately recurred. Thus, understanding the mechanisms regulating the induction of tumor-specific anergy may lead to the development of new therapeutic strategies to enhance CD8 T cell-mediated anti-tumor immunity. In Aim I of this proposal, we will investigate the mechanisms by which the common gamma chain (?c) cytokines IL-2 and IL-4 regulate OX40 receptor expression on CD8 T cells including the molecular mechanisms regulating activation of the OX40 promoter. In Aim II, we will determine the molecular mechanisms by which tumors induce CD8 T cell anergy and test the hypothesis that combined anti-OX40/?c cytokine therapy can restore the function of anergic CTL in tumor-bearing hosts. Aim III seeks to test the hypothesis that anti-OX40 therapy can enhance the differentiation of endogenous tumor-specific CD8 T cells in mice with spontaneously arising prostate cancer and to test whether anti-OX40 therapy promotes the differentiation of tumor-reactive CD8 T cells in cancer patients that are currently being treated with an agonist anti-OX40 mAb in a phase I clinical trial at the EACRI. Taken together, these studies will provide insight into the mechanisms regulating OX40 expression, the molecular basis of tumor- specific CD8 T cell anergy, and whether anti-OX40 therapy can augment the endogenous CD8 T cell response in both tumor-bearing mice and cancer patients.
PUBLIC HEALTH RELEVANCE: These studies will test whether anti-OX40 antibody therapy can enhance CD8 T cell-mediated anti- tumor immunity and enhance the long-term survival of cancer-bearing hosts. Along with the data obtained from an on-going Phase I clinical trial with an anti-OX40 antibody in cancer patients, the results generated in the proposed study will guide the development of future pre-clinical research studies and clinical trials with the potential to directly benefit cancer patients.
描述(由申请人提供):肿瘤特异性CD 8 T细胞外周耐受性可能是产生强效抗肿瘤免疫的主要障碍。最近的研究开始研究通过共刺激分子的信号传导是否可以充分增强免疫反应,以逆转肿瘤特异性耐受并促进抗肿瘤免疫。为此,我们的实验室和其他实验室一直专注于OX 40(CD 134)共刺激分子(肿瘤坏死因子受体(TNFR)超家族成员)的连接增强CD 4和CD 8 T细胞扩增、分化和存活的机制。重要的是,几项研究还表明,OX 40在从荷瘤宿主的肿瘤引流淋巴结分离的T细胞上表达,并且OX 40接合可以增强体内抗肿瘤免疫。还显示0X 40介导的信号传导克服肽诱导的CD 4 T细胞无反应性。最近,我们证明了OX 40连接可以在体内恢复无反应性肿瘤反应性CD 8 T细胞的功能。虽然抗OX 40治疗导致部分肿瘤消退,但肿瘤最终复发。因此,了解调节肿瘤特异性无反应性诱导的机制可能导致开发新的治疗策略以增强CD 8 T细胞介导的抗肿瘤免疫。在本提案的目标I中,我们将研究常见伽马链(?c)细胞因子IL-2和IL-4调节CD 8 T细胞上的0X 40受体表达,包括调节0X 40启动子活化的分子机制。在目的二,我们将确定肿瘤诱导CD 8 T细胞无能的分子机制,并测试的假设,结合抗OX 40/?c细胞因子治疗可恢复荷瘤宿主无反应性CTL的功能。目的III旨在检验抗OX 40治疗可增强自发性前列腺癌小鼠中内源性肿瘤特异性CD 8 T细胞分化的假设,并检验抗OX 40治疗是否促进目前在EACRI I期临床试验中接受激动剂抗OX 40 mAb治疗的癌症患者中肿瘤反应性CD 8 T细胞的分化。总之,这些研究将提供对调节0X 40表达的机制、肿瘤特异性CD 8 T细胞无反应性的分子基础以及抗0X 40疗法是否可以增强荷瘤小鼠和癌症患者中的内源性CD 8 T细胞应答的深入了解。
公共卫生相关性:这些研究将测试抗0X 40抗体疗法是否可以增强CD 8 T细胞介导的抗肿瘤免疫并增强荷癌宿主的长期存活。沿着从正在进行的癌症患者中使用抗OX 40抗体的I期临床试验中获得的数据,拟议研究中产生的结果将指导未来临床前研究和临床试验的发展,这些研究和临床试验有可能直接使癌症患者受益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William L Redmond其他文献
Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
- DOI:
10.1186/2051-1426-1-s1-p82 - 发表时间:
2013-11-01 - 期刊:
- 影响因子:10.600
- 作者:
Stefanie N Linch;Melissa J Kasiewicz;William L Redmond - 通讯作者:
William L Redmond
Professional development session for early career scientists at SITC 2012
- DOI:
10.1186/2051-1426-1-6 - 发表时间:
2013-06-27 - 期刊:
- 影响因子:10.600
- 作者:
Christian M Capitini;William L Redmond;Kimberly A Shafer-Weaver - 通讯作者:
Kimberly A Shafer-Weaver
William L Redmond的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William L Redmond', 18)}}的其他基金
Elucidating the role of intratumoral microbiota on immunotherapy efficacy
阐明肿瘤内微生物群对免疫治疗疗效的作用
- 批准号:
10449202 - 财政年份:2021
- 资助金额:
$ 15.82万 - 项目类别:
Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler
Ox40介导的共刺激克服肿瘤诱导的CD8 T细胞外周耐受
- 批准号:
8294589 - 财政年份:2011
- 资助金额:
$ 15.82万 - 项目类别:
Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler
Ox40介导的共刺激克服肿瘤诱导的CD8 T细胞外周耐受
- 批准号:
8269372 - 财政年份:2011
- 资助金额:
$ 15.82万 - 项目类别:
Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler
Ox40介导的共刺激克服肿瘤诱导的CD8 T细胞外周耐受
- 批准号:
8470084 - 财政年份:2011
- 资助金额:
$ 15.82万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 15.82万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 15.82万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 15.82万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 15.82万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 15.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 15.82万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 15.82万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 15.82万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 15.82万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 15.82万 - 项目类别: